Stefan Zeuzem

90.3k total citations · 15 hit papers
1.0k papers, 47.0k citations indexed

About

Stefan Zeuzem is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Stefan Zeuzem has authored 1.0k papers receiving a total of 47.0k indexed citations (citations by other indexed papers that have themselves been cited), including 665 papers in Hepatology, 578 papers in Epidemiology and 119 papers in Molecular Biology. Recurrent topics in Stefan Zeuzem's work include Hepatitis C virus research (558 papers), Liver Disease Diagnosis and Treatment (438 papers) and Hepatitis B Virus Studies (328 papers). Stefan Zeuzem is often cited by papers focused on Hepatitis C virus research (558 papers), Liver Disease Diagnosis and Treatment (438 papers) and Hepatitis B Virus Studies (328 papers). Stefan Zeuzem collaborates with scholars based in Germany, United States and France. Stefan Zeuzem's co-authors include Christoph Sarrazin, Eva Herrmann, Mireen Friedrich‐Rust, Albrecht Piiper, Heiner Wedemeyer, Bernd Kronenberger, Bettina E. Hansen, Harry L.A. Janssen, Joerg Bojunga and Thomas Berg and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Stefan Zeuzem

986 papers receiving 45.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis

2013 1.9k citations Stefan Zeuzem, Jonel Trebicka et al. Gastroenterology profile →
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

1998 1.9k citations Patrick Marcellin, Stefan Zeuzem et al. profile →
Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

2008 1.1k citations Christoph Sarrazin, Stefan Zeuzem et al. Gastroenterology profile →
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

2012 1.1k citations Heiner Wedemeyer, Jean‐François Dufour et al. profile →
Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

1998 1.1k citations Stefan Zeuzem et al. profile →
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C

2000 954 citations Stefan Zeuzem, J. Rasenack et al. profile →
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

2005 866 citations Harry L.A. Janssen, Stefan Zeuzem et al. profile →
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 771 citations Jean–Pierre Bronowicki, Marc Bourlière et al. profile →
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

2014 646 citations Stefan Zeuzem, Heiner Wedemeyer et al. profile →
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

2007 578 citations Edward Gane, J. Rasenack et al. profile →
Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography

2009 532 citations Eva Herrmann, Stefan Zeuzem et al. profile →
Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

2007 476 citations Christoph Sarrazin, Stefan Zeuzem et al. Gastroenterology profile →
Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database

2011 411 citations Stefan Zeuzem et al. profile →
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

2015 386 citations Stefan Zeuzem et al. profile →
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade

2023 176 citations Fabian Finkelmeier, Kai‐Henrik Peiffer et al. profile →

Peers

Countries citing papers authored by Stefan Zeuzem

Since Specialization

Citations

This map shows the geographic impact of Stefan Zeuzem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Zeuzem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Zeuzem more than expected).

Fields of papers citing papers by Stefan Zeuzem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Zeuzem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Zeuzem. The network helps show where Stefan Zeuzem may publish in the future.

Co-authorship network of co-authors of Stefan Zeuzem

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Zeuzem. A scholar is included among the top collaborators of Stefan Zeuzem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Zeuzem. Stefan Zeuzem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acid Sphingomyelinase Activation and ROS Generation Potentiate Antiproliferative Effects of Mitomycin in HCC 2024 ·International Journal of Molecular Sciences ·(unknown), Stephanie Schwalm, (unknown), Nerea Ferreirós, (unknown), Stefan Zeuzem, Erich Gulbins, Christoph Sarrazin, Josef Pfeilschifter, Georgios Grammatikos	0
2	Impaired HBsAg release and antiproliferative/antioxidant cell regulation by HBeAg‐negative patient isolates reflects an evolutionary process 2024 ·Liver International ·(unknown), (unknown), Mirco Glitscher, (unknown), (unknown), (unknown), (unknown), (unknown), Julia Dietz, Fabian Finkelmeier, Michael Praktiknjo, Jonel Trebicka, Stefan Zeuzem, Christoph Sarrazin, Eberhard Hildt, Kai‐Henrik Peiffer	3
3	Interventional oncological treatment of hepatocellular carcinoma (HCC) - A single-center long-term evaluation of thermoablation techniques like LITT, MWA, and TACE in a multimodal application over 26 years 2023 ·Heliyon ·Thomas J. Vogl, (unknown), Tatjana Gruber‐Rouh, (unknown), Wolf O. Bechstein, Stefan Zeuzem, N Naguib, (unknown)	7
4	Strategietreffen: Virushepatitis in Deutschland eliminieren – Was ist zu tun? 2023 ·Zeitschrift für Gastroenterologie ·Tammo Lambert Tergast, Ulrike Protzer, Stefan Zeuzem, (unknown), Christoph Sarrazin, (unknown), Patrick Ingiliz, Markus Cornberg, Ruth Zimmermann, (unknown), Peter Buggisch, (unknown), Heiner Wedemeyer	0
5	Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma 2023 ·Clinical Oncology ·Scherwin Mahmoudi, Simon Bernatz, Jörg Ackermann, Vitali Koch, Daniel Pinto dos Santos, (unknown), İbrahim Yel, Simon S. Martin, Jan‐Erik Scholtz, (unknown), Dirk Walter, Stefan Zeuzem, Peter J. Wild, Thomas J. Vogl, (unknown)	8
6	The PB1 and the ZZ domain of the autophagy receptor p62/SQSTM1 regulate the interaction of p62/SQSTM1 with the autophagosome protein LC3B 2023 ·Protein Science ·(unknown), (unknown), (unknown), (unknown), Markus A. Hartmann, Ewgenij Proschak, (unknown), (unknown), Stefan Zeuzem, Vladimir V. Rogov, Alejandro E. Leroux, Albrecht Piiper, Ricardo M. Biondi	8
7	Risk Factors and Role of Antibiotic Prophylaxis for Wound Infections after Percutaneous Endoscopic Gastrostomy 2023 ·Journal of Clinical Medicine ·A. W. Mondorf, (unknown), Christiana Graf, (unknown), Irina Blumenstein, M. Jung, Mireen Friedrich‐Rust, Daniel Hack, Silke Besier, Michael Hogardt, Volkhard A. J. Kempf, Stefan Zeuzem, Christoph Welsch, Jörg Bojunga	1
8	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study 2020 ·The Journal of Infectious Diseases ·Milan J. Sonneveld, Bettina E. Hansen, Willem Pieter Brouwer, Henry LY Chan, Teerha Piratvisuth, Jidong Jia, Stefan Zeuzem, Rong‐Nan Chien, Robert J. de Knegt, Cynthia Wat, Vedran Pavlovic, Anuj Gaggar, Qing Xie, Marı́a Buti, Robert A. de Man, Harry L.A. Janssen, (unknown)	11
9	The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection 2016 ·Liver International ·Tony Bruns, Philipp A. Reuken, Sven Stengel, Ludmila Gerber, Beate Appenrodt, (unknown), Frank Lammert, Stefan Zeuzem, Andreas Stallmach	34
10	Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct – a potential novel tool for differential diagnosis of indeterminate biliary stricture 2016 ·Histopathology ·Dirk Walter, Eva Herrmann, Ria Winkelmann, Jörg Albert, Juliane Liese, Andreas A. Schnitzbauer, Stefan Zeuzem, Martin‐Leo Hansmann, Jan Peveling‐Oberhag, Sylvia Hartmann	9
11	Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma 2015 ·Cancer Research ·Christian Schmithals, Verena Köberle, Hüdayi Korkusuz, Thomas Pleli, (unknown), (unknown), Ahmed Atef Ibrahim, José M. Arencibia, Vida Vafaizadeh, Bernd Groner, Horst‐Werner Korf, Bernd Kronenberger, Stefan Zeuzem, Thomas J. Vogl, Oliver Waidmann, Albrecht Piiper	54
12	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis 2014 ·Antimicrobial Agents and Chemotherapy ·Stefan Zeuzem, Vincent Soriano, Tarik Asselah, Edward Gane, Jean–Pierre Bronowicki, Peter Angus, Ansgar W. Lohse, Felix Stickel, Beat Müllhaupt, Stuart K. Roberts, Marcus Schuchmann, Michael P. Manns, Marc Bourlière, Marı́a Buti, Jerry O. Stern, (unknown), Florian Voß, John P. Sabo, Wulf O. Böcher, Federico Mensa	8
13	Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis 2013 ·Clinical Cancer Research ·Inga Hinrichsen, Angela Brieger, Jörg Trojan, Stefan Zeuzem, Mef Nilbert, Guido Plotz	26
14	Predictors associated with treatment initiation and switch in a real‐world chronic hepatitis B population from five European countries 2013 ·Journal of Viral Hepatitis ·Hakan Leblebicioğlu, Victoria Aramă, Xavier Causse, Patrick Marcellin, Reşat Özaras, (unknown), Krzysztof Simon, Andra‐Iulia Suceveanu, Manfred Wiese, Stefan Zeuzem, (unknown), (unknown), S. Björk, Bénédicte Lescrauwaet, (unknown), Jean‐Pierre Zarski, (unknown)	8
15	Improved Platelet Count and Smaller Spleen Size Long After Sustained Virological Response in Chronic Hepatitis C Patients With Advance Fibrosis 2011 ·Bern Open Repository and Information System (University of Bern) ·(unknown), (unknown), (unknown), Heiner Wedemeyer, Jean‐François Dufour, Frank Lammert, Andrés Duarte‐Rojo, (unknown), (unknown), (unknown), Stefan Zeuzem, (unknown), Robert J. de Knegt, (unknown), (unknown)	1
16	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms 2011 ·PLoS ONE ·Martin Lagging, Galia Askarieh, Francesco Negro, Stéphanie Bibert, Jonas Söderholm, Johan Westin, Magnus Lindh, Ana I. Romero, Gabriele Missale, Carlo Ferrari, Avidan U. Neumann, Jean–Michel Pawlotsky, Bart L. Haagmans, Stefan Zeuzem, Pierre–Yves Bochud, Kristoffer Hellstrand, (unknown)	122
17	PREDICTION OF RESPONSE TO PEGINTERFERON-ALFA IN HBEAG POSITIVE CHRONIC HEPATITIS B: A MODEL BASED ON 721 PATIENTS 2008 ·Data Archiving and Networked Services (DANS) ·Erik H.C.J. Buster, Bettina E. Hansen, George Lau, Teerha Piratvisuth, Philip McCloud, Peter Button, Ewout W. Steyerberg, Stefan Zeuzem, Harry L.A. Janssen	0
18	Impact of NS5A Sequences of Hepatitis C Virus Genotype 1a on Early Viral Kinetics during Treatment with Peginterferon‐α2a plus Ribavirin 2007 ·The Journal of Infectious Diseases ·Francesca Dal Pero, (unknown), M. Gerotto, Gladis Bortoletto, (unknown), Eva Herrmann, Stefan Zeuzem, A. Albertí, Nikolai V. Naoumov	13
19	Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C 2005 ·Gastroenterology ·Michael Wagner, M Huber, Thomas Berg, Holger Hinrichsen, J. Rasenack, Tobias Heintges, A Bergk, Christine Bernsmeier, Dieter Häussinger, Eva Herrmann, Stefan Zeuzem	319
20	Fulminant Hepatitis A in a Patient with Severe Hyperthyroidism: Rapid Recovery from Hepatic Coma after Plasmapheresis and Total Thyroidectomy 2000 ·The Journal of Clinical Endocrinology & Metabolism ·(unknown), Klaus Badenhoop, Stefan Zeuzem, (unknown), Christoph Betz, A. Encke, K. H. Usadel	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact